Michel Janicot

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

NPTXR as a novel therapeutic target: efficacy of antibody-drug conjugates in preclinical tumor models.

NPTXR as a novel therapeutic target: efficacy of antibody-drug conjugates in preclinical tumor models.

Journal: Cancer cell international
Published: November 11, 2025

PCO25-210: Design of Novel Antibody Drug Conjugates Using a Fully Humanized Monoclonal Antibody Targeting the Human Neuronal Pentraxin Receptor (YB800-ADCs) for Therapeutic Intervention in Oncology.

PCO25-210: Design of Novel Antibody Drug Conjugates Using a Fully Humanized Monoclonal Antibody Targeting the Human Neuronal Pentraxin Receptor (YB800-ADCs) for Therapeutic Intervention in Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2025

INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death.

INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death.

Journal: Oncotarget
Published: July 15, 2024

Tolerability of long-term temperature controlled whole-body thermal treatment in advanced cancer-bearing dogs.

Tolerability of long-term temperature controlled whole-body thermal treatment in advanced cancer-bearing dogs.

Journal: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
Published: December 23, 2021

Safety evaluation of long-term temperature controlled whole-body thermal treatment in female Aachen minipig.

Safety evaluation of long-term temperature controlled whole-body thermal treatment in female Aachen minipig.

Journal: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
Published: February 12, 2021

Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology.

Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology.

Journal: Oncotarget
Published: October 16, 2020

Transcriptome-wide analysis reveals insight into tumor suppressor functions of 1B3, a novel synthetic miR-193a-3p mimic.

Transcriptome-wide analysis reveals insight into tumor suppressor functions of 1B3, a novel synthetic miR-193a-3p mimic.

Journal: Molecular therapy. Nucleic acids
Published: July 16, 2020

TGF-β2 silencing to target biliary-derived liver diseases.

TGF-β2 silencing to target biliary-derived liver diseases.

Journal: Gut
Published: May 15, 2019

Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas.

Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 13, 2017

An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages.

An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 16, 2017

First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery.

First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery.

Journal: PloS one
Published: January 04, 2017

Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma.

Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma.

Journal: Molecular cancer therapeutics
Published: July 14, 2016
Showing 1-12 of 15

Last Updated: 09/26/2026